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Effective Treatment of Psoriasis with Narrow-Band
UVB Phototherapy Is Linked to Suppression of the
IFN and Th17 Pathways
Em +oke Ra´cz1,2, Errol P. Prens1,2, Dorota Kurek3, Marius Kant1,2, Dick de Ridder4, Sabine Mourits1,2,
Ewout M. Baerveldt1,2, Zeliha Ozgur5, Wilfred F.J. van IJcken5, Jon D. Laman2, Frank J. Staal2 and
Leslie van der Fits1,2
Narrow-band ultraviolet-B (NB-UVB) phototherapy is an effective treatment for psoriasis. The molecular
mechanisms underlying its efficacy are incompletely understood. To identify NB-UVB-induced molecular
pathways that may account for its anti-inflammatory efficacy, gene expression profiling was performed using
epidermal RNA from lesional and nonlesional skin from patients with psoriasis undergoing NB-UVB therapy.
Downregulation of Th17 signaling pathway was observed during NB-UVB therapy in psoriatic epidermis. Strong
inhibition of the Th17 pathway by UVB was confirmed in an ex vivo organ culture system by demonstrating
reduced signal transducer and activator of transcription 3 (STAT3) phosphorylation and b-defensin-2
production. These results were further substantiated by demonstrating that NB-UVB inhibited the Th17-
dependent psoriasis-like dermatitis in mice. Other pathways affected by NB-UVB therapy include the IFN
signaling pathway, epidermal differentiation, and other well-known therapeutic targets in psoriasis, such as
the glucocorticoid, vitamin D, peroxisome proliferator-activated receptor, and IL-4 signaling pathways.
In conclusion, clinical improvement of psoriasis by NB-UVB is linked to suppression of Th17 and type I and
type II IFN signaling pathways, which are critical in the pathogenesis of the disease. Our results show that
clinically effective NB-UVB therapy is based on suppression of a broad range of important molecular pathways
in psoriatic skin.
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INTRODUCTION
Narrow-band ultraviolet-B (NB-UVB) phototherapy is a
standard treatment for psoriasis. Its mechanism of action is
incompletely understood and has mainly been studied
in vitro and in mice.
Locally, NB-UVB therapy reverses several pathologic alte-
rations in psoriasis: the number of epidermal T lymphocytes
and dendritic cells (DCs) decrease during phototherapy
(Ozawa et al., 1999; Walters et al., 2003; Carrascosa
et al., 2007; Erkin et al., 2007). T cells exhibit a functional
shift toward less IFN-g and more IL-4-production after UVB
treatment (Piskin et al., 2003; Piskin et al., 2004), and NB-UVB
therapy reduces keratinocyte proliferation (Erkin et al., 2007).
The molecular mechanisms of these NB-UVB effects are
unknown. UVB radiation is mostly absorbed by the epidermis,
which is considered the primary target of UVB action.
We used gene expression profiling in order to identify
pathways and mechanisms that are involved in the anti-
inflammatory effect of NB-UVB. In addition, the effects of
NB-UVB were investigated in the recently described and, on
the molecular level, well-characterized, imiquimod-induced
psoriasis-like dermatitis mouse model (van der Fits et al.,
2009).
To date, the transcriptomic effects of NB-UVB have only
been examined in nonlesional skin samples of three patients
with psoriasis (Hochberg et al., 2007). NB-UVB-induced
differentially expressed genes included S100A proteins,
DC markers, tumor necrosis factor-a target genes, matrix
metalloproteinases, and NF-kB target genes. In addition,
IGF-binding protein-7 was identified as an antiproliferative
molecule with low expression in nonlesional psoriatic skin,
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which was induced by NB-UVB phototherapy, possibly
counting for its antipsoriatic effect (Hochberg et al., 2007).
We analyzed epidermal gene expression profiles in lesional
and nonlesional skin of 11 patients with psoriasis taken
before and after standard NB-UVB treatment. Additionally,
in the same patients, the short-term molecular effects of
NB-UVB were investigated. Specific pathways affected by
NB-UBV in psoriasis patients were further examined in vitro
and validated in a psoriasis-like dermatitis mouse model.
RESULTS
Clinical efficacy of NB-UVB therapy
The mean psoriasis area and severity index (PASI) reduction
after standard NB-UVB therapy in all patients included in this
study (n¼11) was 84.1% (range 58–100%) (Supplementary
Table S4 online). The mean PASI score decreased from 14.4
(range 10.0–31.0) to 2.4 (range 0–8.4). For microarray
analysis, patient samples were pooled in two groups, each
containing four patients (pool A and pool B, Supplementary
Table S5 online). The mean PASI reduction was similar
in these two groups of patients.
Correlation of gene expression profiles
The degree of similarity between global gene expression
profiles was assessed using the OmniViz package (OmniViz,
Maynard, MA). Expression profiles of the two pools of patient
samples were similar for all conditions, demonstrating valid
duplicate measurements.
Two major clusters of samples were identified on the basis
of strong similarities in gene expression (Figure 1). Lesional
skin biopsies taken before therapy formed the first cluster.
The second larger cluster could be divided into three smaller
subclusters (Figure 1) that are formed by combinations of
lesional skin biopsies taken at 50% PASI reduction, or at the
end of the treatment, together with nonlesional biopsies
(Figure 1). These second three subclusters were quite similar
to each other, indicating that gene expression in lesional skin
taken at 50% PASI reduction and at the end of treatment was
highly similar to that of nonlesional skin. Thus, NB-UVB
therapy induced a shift in gene expression in lesional skin
toward that of nonlesional skin.
Differences between untreated lesional and nonlesional
epidermis
Gene expression profiles of untreated psoriasis lesions were
compared with untreated nonlesional skin. In lesional skin,
251 genes were upregulated and 383 genes downregulated
compared with nonlesional skin, similarly to previously
reported profiles in untreated lesional and nonlesional
psoriatic skin (Bowcock et al., 2001; Oestreicher et al.,
2001; Zhou et al., 2003; Kulski et al., 2005; Quekenborn-
Trinquet et al., 2005; Mee et al., 2007; Reischl et al., 2007;
Yao et al., 2008; Gudjonsson et al., 2010a, b), although these
studies extracted RNA from whole skin biopsies whereas we
exclusively analyzed epidermal RNA. The genes upregulated
in lesional skin included members of the type I and type II
IFN signaling pathway, Th17 pathway, innate cytokine genes,
and other immune response genes; epidermal differentiation-
associated genes, and proteinases such as kallikreins and
cathepsin C. Genes expressed higher in nonlesional skin were
involved in cell proliferation, cell cycle progression, and
epidermal differentiation.
Genes affected by NB-UVB phototherapy in lesional and
nonlesional epidermis
The genes up- or down-regulated in lesional and nonlesional
skin after 12 weeks of NB-UVB therapy are shown in Supple-
mentary Tables S1–S3 online. There was only a marginal
overlap between genes regulated in lesional and nonlesional
skin by NB-UVB. Five of these were downregulated (S100A9,
keratin 6, a-actinin, STEAP4, and ets homologous factor), and
one, betacellulin, upregulated.
Transcriptome analysis of psoriatic lesions showed
that NB-UVB strongly suppressed genes of the Th17 and
IFN signaling pathways and members of the epidermal
differentiation complex (Table 1).
The functional annotation of the differentially expressed
genes in lesional skin before versus after NB-UVB therapy is
shown in Supplementary Figure S1 online. The expression of
immune response genes and of genes involved in antiviral
responses and stress responses was suppressed by NB-UVB
therapy, whereas genes involved in epidermis development,
extracellular matrix components, and negative regulators of
biological processes were induced.
NB-UVB therapy affects recognized therapeutic targets in psoriasis
Ingenuity Pathway Analysis software (Ingenuity Systems,
www.ingenuity.com) was additionally used to identify
Cluster
Sample
Time
Pool
1
3
3
2
2
1
4
4
L
L
L
LLLL
L
NL
NL
NL
NLNLNL
T0
T0
T0
T0 D D
D
D
D
D
EEE
E
E
E
A
A
A
A
A
AAAAA
B
B
B
B
B
B
BBBBBB
Co
rre
la
tio
n
1
0.9
0.8
0.7
0.6
0.5
0.4
Figure 1. Correlation view of expression profiles of the different epidermal
RNA samples. The degree of similarity between global gene expression
profiles was assessed using the OmniViz package. The red squares indicate
positive pairwise correlations (equality in gene expression between clusters)
and blue squares indicate negative pairwise correlations. A, B, patient pools;
D, sample taken at 50% psoriasis area and severity index (PASI) reduction;
E, sample taken after completion of narrow-band ultraviolet-B (NB-UVB)
therapy; L, lesional samples; NL, nonlesional samples; T0, sample taken
before the first irradiation.
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over-represented signaling pathways that were affected by
NB-UVB therapy in psoriasis lesions. As shown in Table 2,
we found that NB-UVB regulated pathways that are:
1. recognized therapeutic targets in psoriasis, such
as glucocorticoid receptor and vitamin D receptor
signaling.
2. previously identified as potential therapeutic targets in
psoriasis, such as peroxisome proliferator-activated
receptor and IL-4 and IL-10 signaling (Asadullah et al.,
2003; Ghoreschi et al., 2003; Martin, 2003; Robertshaw
and Friedmann, 2005; Sertznig et al., 2008; Docke
et al., 2009).
3. described as targets of UV radiation in normal skin and
that are simultaneously involved in the pathogenesis of
psoriasis, such as NF-kB, mitogen-activated protein
kinase, p53, and IGF-1 signaling.
Successful NB-UVB treatment of psoriasis is associated with
downregulation of the Th17 pathway in lesional skin
Among the genes most downregulated during NB-UVB
phototherapy in lesional skin were many known members
of the Th17 pathway (Figure 2a). From these, S100A9 and
b-defensin-2 were selected to validate the microarray data.
Using mRNA of individual patients, we confirmed the
Table 1. IFN signaling, Th17 pathway, and epidermal differentiation are affected by NB-UVB phototherapy in the
lesional epidermis
Fold change at PASI 50% Fold change at the end of treatment
Name Symbol Average Pool A Pool B Average Pool A Pool B
Th17 pathway
Signal transducer and activator of transcription 3 STAT3 1.8k 1.8 1.7 2.5k 3.1 2.2
S100 calcium binding protein A7 S100A7 30.2k 132.3 7.3 36.5k 151.7 11.7
Defensin, b-2 DEFB4 28.2k 123.4 6.3 36.2k 121.2 11.6
Peptidase inhibitor 3, skin-derived (SKALP) SKALP 8.9k 26.3 4.1 24.7k 45.7 14.4
S100 calcium binding protein A9 S100A9 5.3m (NS) 17.2 1.5 17.7k 79.1 3.5
S100 calcium binding protein A12 S100A12 10.8k 32.7 4.2 15.3k 29.3 13.4
Keratin 16 KRT16 4.6k 13.1 1.6 12.9k 20.0 8.5
Lipocalin 2 (oncogene 24p3) LCN2 12.0k 37.0 3.9 11.6k 557.4 9.8
Serpin peptidase inhibitor, clade B (ovalbumin), member 3 SERPINB3 4.2k 5.4 3.1 10.4k 19.4 4.7
IL 8 IL8 6.0k 12.4 3.4 5.0k 10.2 3.4
IFN signaling
Signal transducer and activator of transcription 1 STAT1 1.3k 2.3 1.1 3.7k 5.3 3.4
Myxovirus resistance 1, IFN-inducible protein p78 (mouse) MX1 2.5k 4.0 1.5 4.3k 6.3 3.6
IFN-g receptor 1 IFNGR 1.4k 1.4 1.1 2.1k 2.2 2.2
20-50-oligoadenylate synthetase 2, 69/71 kDa OAS2 1.8k 3.4 1.5 3.4k 5.2 2.9
IFN, a-inducible protein 6 IFI6 2.2k 3.3 1.5 4.6k 6.7 4.1
Keratin 17 KRT17 3.0k 9.1 1.9 9.5k 8.8 10.8
IFN induced with helicase C domain 1/melanoma
differentiation associated gene 5
IFIH1/MDA5 1.0 1.2 0.8 1.8k 2.5 1.5
Epidermal differentiation
GATA binding protein 3 GATA3 2.8m 3.1 2.4 2.9m 3.8 2.5
Corneodesmosin CDSN 1.7m 1.6 1.7 2.1m 1.8 2.6
Keratin 6 KRT6 3.6k 9.2 1.3 9.7k 19.2 4.4
Small proline-rich protein 2C SPRR2C 11.0k 16.2 8.4 9.6k 18.6 7.1
Desmocollin 2 DSC2 1.8k 3.1 1.5 5.4k 5.2 7.7
Keratin 15 KRT15 3.2m 3.1 3.2 3.7m 3.3 4.4
Transglutaminase K TGM1 1.9k 1.7 2.1 2.4k 2.5 2.4
Abbreviations: NB-UVB, narrow-band ultraviolet-B; NS, statistically not significant; PASI, psoriasis area and severity index.
k indicates downregulation; m indicates upregulation.
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downregulation of S100A9 by quantitative real-time PCR
(RT-PCR; Figure 2b). No clearcut correlation between the
S100A9 mRNA levels and the individual PASI scores was
observed (Pearson’s correlation test, data not shown). Down-
regulation of b-defensin-2 protein expression during NB-UVB
phototherapy in lesional psoriatic skin was confirmed by
immunofluorescent staining (Figure 2c).
To examine whether UVB has an early local effect
(not requiring systemic involvement or an associated
immunologic network) on the Th17 pathway, or whether its
downregulation is a consequence of the improvement of
psoriasis, in vitro experiments were performed. Skin explants
were stimulated with the Th17-associated cytokine IL-22,
which is known to induce a psoriasis-like phenotype
in reconstituted human epidermis, including induction
of acanthosis, antimicrobial peptides such as human
b-defensins, and activation of signal transducer and activator
of transcription 3 (STAT3; Sa et al., 2007; Eyerich et al.,
Table 2. Effect of narrow-band ultraviolet-B (NB-UVB) phototherapy on pathways known to be therapeutic targets
in psoriasis, or targets of UVB radiation
Molecules affected by NB-UVB within these pathways
Pathway P-value Upregulated Downregulated
Therapeutic target in psoriasis
Glucocorticoid receptor
signaling
1.1E03 PIK3R1, PIK3C2G, HSPA2, BCL2, IL1R2, TGFBR2,
TSC22D3, KAT2B, AKT3, NCOR2, ADRB2, UBE2I
IL8, STAT3, STAT1
VDR/RXR activation 4.2E03 IGFBP5, NCOR2, CST6 DEFB4, SERPINB1, KLK6, HSD17B2
NF-kB signaling 2.3E02 IL1R2, CSNK2A2, IL18, PIK3R1, PIK3C2G, AKT3, IL1F7 IL1F9
Induced by UV in normal skin
p53 signaling 2.1E03 KAT2B, TP53INP1, PIK3R1, PIK3C2G, AKT3, CCND1, BCL2 SCO2
p38 MAPK signaling 3.5E03 IL1R2, TGFBR2, IL18, H3F3B, IL1F7, EEF2K IL1F9, STAT1
EGF signaling 5.4E03 CSNK2A2, PIK3R1, PIK3C2G STAT3, STAT1
IGF-1 signaling 2.4E02 CSNK2A2, PIK3R1, PIK3C2G, AKT3, IGFBP5, IGFBP7
Proposed as therapeutic target in psoriasis
LXR/RXR activation 2.5E04 IL1R2, APOE, IL18, IL1F7, NCOR2 IL1F9, LDLR, CCL7
IL-10 signaling 4.2E03 IL1R2, IL18, IL1F7 IL4R, IL1F9, STAT3
PPAR signaling 1.8E02 IL1R2, IL18, IL1F7, NCOR2, PDGFC IL1F9
IL-4 signaling 2.2E02 PIK3R1, PIK3C2G, AKT3 IL4R, IL13RA1
Other
GM-CSF signaling 1.5E04 PIK3R1, PIK3C2G, AKT3, CCND1 CSF2RB, LYN, STAT3, STAT1
Acute-phase response
signaling
3.2E04 PIK3R1, SOCS6, IL1F7, IL18, AKT3 C1S, SERPINA3, STAT3, C1R, IL1F9,
SOD2, CRABP2, CFB
IFN signaling 6.3E04 IFIT1, OAS1, IFNGR1, MX1, STAT1
PDGF signaling 2.1E03 CSNK2A2, PIK3R1, CAV1, PIK3C2G, PDGFC STAT3, STAT1
JAK/Stat signaling 4.2E03 PIK3R1, SOCS6, PIK3C2G, AKT3, STAT3, STAT1
IL-6 signaling 7.2E03 IL1R2, CSNK2A2, IL18, IL1F7 IL8, IL1F9, STAT3
Complement system 9.5E03 CD59 C1R, C1S, CFB
LPS/IL-1-mediated
inhibition of RXR function
1.9E02 IL1R2, GSTA3, APOE, ALDH3A2, CAT, HS3ST6, ABCC4 ALDH1A3, PAPSS2, HS3ST3A1
VEGF signaling 1.9E02 PIK3R1, PIK3C2G, AKT3, BCL2 HIF1A, ACTN1
Wnt/b-catenin signaling 2.2E02 TGFBR2, CSNK2A2, FRZB, DKK3, SOX10, AKT3, CCND1 SOX9, FZD5
Xenobiotic metabolism
signaling
3.2E02 GSTA3, ALDH3A2, PIK3R1, MAF, CAT, PIK3C2G, HS3ST6,
NCOR2,
ALDH1A3, UGT1A9, HS3ST3A1
Fc
P
RI signaling 3.6E02 FYN, VAV3, PIK3R1, PIK3C2G, AKT3 LYN
IL-2 signaling 4.3E02 CSNK2A2, PIK3R1, PIK3C2G, AKT3
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2009). NB-UVB irradiation of IL-22-stimulated skin biopsies
blocked IL-22-induced STAT3 phosphorylation (Figure 2d
and e). In addition, the IL-22-induced expression of
human b-defensin-2 in the epidermis (Liang et al., 2006; Sa
et al., 2007) was also drastically inhibited by NB-UVB
(Figure 2f).
Taken together, we demonstrate that improvement of
psoriasis by NB-UVB is accompanied by suppression of the
Th17 pathway in the psoriatic epidermis, and that in vitro
already a single NB-UVB dose leads to suppression of the
epidermal effects of the Th17 cytokine IL-22.
Successful NB-UVB therapy of psoriasis is accompanied by
downregulation of the IFN signaling pathway in the epidermis
In psoriasis lesions, members of the IFN signaling pathway
and several IFN-inducible genes were downregulated during
NB-UVB therapy (Figure 3a). We selected the type I
IFN-inducible cytoplasmic RNA receptor IFIH1/MDA5 (IFN
induced with helicase C domain 1/melanoma differentiation
associated gene 5) to validate the microarray data using
mRNA of individual patients, including skin biopsies taken at
50% clinical improvement. IFIH1/MDA5 mRNA was down-
regulated in lesional skin and remained unchanged in
nonlesional skin, confirming the microarray data (Figure
3b), whereas no significant correlation between PASI score
and IFIH1 mRNA levels was observed in the individual
patients (Pearson’s correlation test, data not shown).
The downregulation of type I IFN signaling at the protein
level was verified by immunostaining for MxA protein
expression, a key marker of type I IFN signaling. The
expression of MxA showed a marked decrease in lesional
psoriatic skin treated with NB-UVB (Figure 3c).
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Figure 2. Successful narrow-band ultraviolet-B (NB-UVB) therapy of psoriasis is associated with suppression of the Th17 pathway. (a) Th17 pathway.
Gray indicates gene downregulation. (b) Epidermal S100A9 (S100 calcium binding protein A9) mRNA expression was measured by real-time PCR (RT-PCR).
ABL1 (Abelson murine leukemia viral (v-abl) oncogene homolog 1) was used as an internal control gene. Black bars show lesional and gray bars show
nonlesional psoriatic samples; psoriasis area and severity index (PASI) 50% is sample taken at 50% PASI score reduction. Error bars indicate SEM, n¼ 4 patients.
(c) b-Defensin-2 in psoriasis during NB-UVB therapy, as determined by immunofluorescent staining with a monoclonal anti-b-defensin-2 antibody in lesional
skin biopsies taken before, during, and after NB-UVB therapy. Scale bar¼ 200mm. (d–f) A single NB-UVB irradiation counteracts the effects of IL-22 in vitro.
Normal skin biopsies were obtained from healthy volunteers. Biopsies were cultured with or without recombinant human IL-22 (50 ngml–1) in the culture
medium. After 16 hours in culture, biopsies were irradiated with a single NB-UVB dose of 600mJ cm–2. The cultured biopsies were collected 6 hours after UV
irradiation. Phosphorylated signal transducer and activator of transcription 3 (STAT3) staining of the collected biopsies was performed using a monoclonal
phospho-STAT3 antibody. Phospho-STAT3-positive cells in the epidermis were counted, and represented as mean±SEM (n¼ 4) (e) and a representative example
is shown (d). Scale bar for panel d¼20 mm. (f) Epidermal b-defensin-2 mRNA expression was measured by real-time PCR (RT-PCR). ABL1 was used as an
internal control gene. Error bars indicate SEM, n¼ 4 subjects.
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During NB-UVB therapy induction of normal epidermal
differentiation was observed
Many genes that are linked to terminal epidermal differentia-
tion were affected during NB-UVB therapy according to our
microarray (Table 1). Corneodesmosin gene was selected
to validate the microarray results by RT-PCR using mRNA
from individual patients. Corneodesmosin mRNA expres-
sion was significantly decreased during NB-UVB therapy
(Figure 3d), whereas no clearcut correlation between
PASI score and CDSN mRNA levels could be observed in
the individual patients (Pearson’s correlation test, data not
shown). Microarray data were also validated by demons-
trating a decreased protein expression of keratinocyte
transglutaminase, an enzyme important in epidermal differ-
entiation, after NB-UVB therapy (Figure 3e).
Th17 and epidermal differentiation are important target
pathways of NB-UVB in the psoriasiform dermatitis
model in mice
Imiquimod-induced psoriasiform dermatitis in mice is
mediated via the Th17 pathway (van der Fits et al., 2009).
We investigated whether NB-UVB affected this type of skin
inflammation. In imiquimod-induced psoriasiform dermatitis
erythema, scaling and thickness were clearly reduced after
NB-UVB irradiation (Figure 4d). Epidermal thickness, the
number of CD11cþ DCs, the number of epidermal neutro-
phils, and angiogenesis were all reduced in imiquimod plus
NB-UVB-treated mouse skin when compared with those
treated with imiquimod alone (Figure 4a–c). Thus, as in
human psoriasis, NB-UVB irradiation resulted in a clear
improvement of the psoriasiform skin inflammation in mice,
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Figure 3. Successful narrow-band ultraviolet-B (NB-UVB) therapy of psoriasis is accompanied by inhibition of IFN signaling pathways and induction of
normal epidermal differentiation. (a) IFN signaling pathways. Gray color indicates gene downregulation. (b, d) Epidermal IFN induced with helicase C domain
1/melanoma differentiation associated gene 5 (IFIH1/MDA5; b) and corneodesmosin (CDSN; d) mRNA expression was measured by real-time PCR (RT-PCR).
ABL1 (Abelson murine leukemia viral (v-abl) oncogene homolog 1) was used as an internal control gene. Black bars show lesional and gray bars show
nonlesional psoriatic samples; psoriasis area and severity index (PASI) 50% is sample taken at 50% PASI score reduction. Error bars indicate SEM, n¼ 5 patients.
(c, e) MxA (c) and transglutaminase K (e) protein expression (red staining) during NB-UVB therapy, as determined by immunostaining in lesional psoriatic skin
samples taken before, during, and after NB-UVB therapy. Representative examples of five patients are shown. Scale bar¼ 100mm.
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as assayed by clinical, histological, and immunohistochem-
ical parameters.
To determine whether NB-UVB affects the Th17 pathway
and epidermal differentiation in this murine psoriasiform model,
we performed immunofluorescent staining for STAT3 activation,
and for keratin 1/10. NB-UVB treatment induced a clear
reduction in phosphorylated STAT3 and induced the expression
of keratin 1/10 (epidermal orthodifferentiation; Figure 4e–g).
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Figure 4. Improvement of the imiquimod-induced psoriasiform dermatitis in mice by narrow-band ultraviolet-B (NB-UVB) is accompanied by a reduction of
epidermal phospho-signal transducer and activator of transcription 3 (STAT3) staining and by induction of normal differentiation. BALB/c mice were treated
daily with IMQ cream or control cream on the shaved back skin, and irradiated or sham-irradiated every other day with NB-UVB, starting on the first day
of imiquimod treatment. (a–c) Mice were killed on day 6. Imiquimod-induced inflammation was studied on sections made from the back skin of the mice.
Immunohistochemical staining of myeloid dendritic cells (CD11c, a), granulocytes (GR1, b), and endothelial cells (MECA-20, c) is shown. Scale bars¼100 mm.
(d) Erythema, scaling, and thickness of the back skin were scored daily on a scale from 0 to 4. The cumulative score (erythema plus scaling plus thickness) is
shown. Symbols indicate mean score±SEM of three mice per group. (e) The number of phospho-STAT3-positive cells were counted in three photos made of
different sections by two independent researchers, and are shown relative to the total number of epidermal cells per section. Error bars indicate the SEM.
(f) Immunofluorescent staining for phosphorylated STAT3 of the back skin of the mice. Scale bar¼ 20mm. (g) Keratin 1/10 immunofluorescent staining
of the back skin is shown. Scale bar¼100 mm.
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Thus, as observed in patients with psoriasis, NB-UVB
suppresses the psoriasiform dermatitis in mice, which is
accompanied by downmodulation of the Th17 pathway and
by induction of epidermal orthodifferentiation.
The first NB-UVB dose has minor effects in lesional skin after
6 hours, whereas in nonlesional skin marked gene expression
changes are observed
To study the short-term effects of NB-UVB on gene
expression in psoriatic skin, skin biopsies were taken before
and 6 hours after the first irradiation. In lesional skin, only
three genes (CYP1B1 (cytochrome P450, subfamily I, poly-
peptide 1), periostin, and cryptochrome 1) were significantly
(42-fold) upregulated 6 hours after the first irradiation.
Of these, the upregulation of periostin and cryptochrome
persisted in lesional skin after 3 months of treatment.
Assessment of cryptochrome 1 expression by RT-PCR using
RNA samples from individual patients confirmed the micro-
array results (Figure 5a).
In contrast, in nonlesional skin, the same NB-UVB dose
modulated the expression of 272 genes42-fold, 6 hours after
the first irradiation, whereas none of these were affected in
lesional skin.
To investigate whether the limited response to NB-UVB in
lesional epidermis was because of incomplete penetration of
NB-UVB into the thickened psoriatic epidermis, immunos-
taining for cyclobutane pyrimidine dimers (CPDs) as marker
of UV damage was performed on lesional and nonlesional
biopsies taken before and 15minutes after the first UV
irradiation (70% minimal erythema dose). Robust CPD
positivity was observed in almost all epidermal layers of the
psoriatic plaque (Figure 5b and c). Thus, the relatively small
number of genes affected by a single NB-UVB dose
in lesional skin is not because of the lack of penetration of
NB-UVB in lesional epidermis.
The short-term response to NB-UVB was also evaluated in
lesional and nonlesional skin at 50% clinical improvement.
At this time point, NB-UVB modulated the expression of
65 genes in lesional and 63 genes in nonlesional skin. There
was, again, a limited overlap (11 genes).
NB-UVB and ustekinumab induce different molecular changes
in nonlesional psoriatic skin
The importance of the Th1/Th17 pathways and the abnormal
epidermal differentiation in the pathogenesis of psoriasis is
well known. In order to compare the effects of two different
systemic therapies on epidermal gene expression profiles, the
expression of selected genes of the Th1, Th17, and epidermal
differentiation pathways was analyzed in nonlesional epi-
dermis of patients with psoriasis treated with the anti-IL-12/23
p40 (ustekinumab). Nonlesional skin biopsies were collected
before treatment and at 50% PASI score reduction, whereby
RNA was extracted from the separated epidermis. RT-PCR
analysis of the expression of b-defensin-2, S100A7, IFIH1/
MDA5, and GATA3 (GATA binding protein 3) showed that
the molecular effects of ustekinumab in the epidermis were
different from that of NB-UVB therapy (Figure 6).
DISCUSSION
Our results show that clinically effective NB-UVB therapy
is associated with suppression of type I and type II IFN
signaling, downmodulation of the Th17 pathway, and
modulation of genes involved in epidermal differentiation
in lesional psoriatic epidermis.
IL-23 and the Th17 cytokines IL-17, IL-22, and IL-21 are
key cytokines in the pathogenesis of psoriasis (Blauvelt, 2008;
Nograles et al., 2010). IL-23 is overproduced in psoriasis
lesions, and this cytokine stimulates Th17 cells to produce
Th17 cytokines (Lee et al., 2004; Piskin et al., 2006; Wilson
et al., 2007). The prototypic Th17 cytokine IL-22 is a potent
stimulator of keratinocyte proliferation and of the production
of antimicrobial peptides, thereby representing a key effector
cytokine in the pathogenesis of psoriasis (Wolk et al., 2006;
Sa et al., 2007; Nograles et al., 2008; Eyerich et al., 2009).
Polymorphisms in genes encoding IL-23 receptor and IL12/
IL23p40 are associated with susceptibility to psoriasis
(Cargill et al., 2007; Nair et al., 2008). Biologics targeting
IL12/IL23p40 are highly effective in psoriasis (Krueger et al.,
2007). The Th17 pathway is also rapidly inhibited in psoriatic
skin during treatment with cyclosporine A and etanercept
(Zaba et al., 2007). Cyclosporine A modulation of this
pathway is observed within 2 weeks after the start of
treatment and correlates well with the clinical improvement
(Haider et al., 2008).
The suppressive effects of NB-UVB therapy on the IL-23/
IL-17 axis in psoriasis have recently been shown by
immunohistochemistry and RT-PCR analysis of lesional skin
(Johnson-Huang et al., 2010). Suppression of the IL-23/IL-17
5.0
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Figure 5. Short-term epidermal effects of narrow-band ultraviolet-B (NB-
UVB). (a) Epidermal mRNA expression of cryptochrome 1 (CRY1) before and
6hours after the first irradiation with NB-UVB (UVB dose was 70% of the
minimal erythema dose (MED)), as measured by real-time PCR (RT-PCR).
ABL1 (Abelson murine leukemia viral (v-abl) oncogene homolog 1) was
used as an internal control gene. Black bars: before irradiation, gray
bars: 6 hours after irradiation. Error bars indicate SEM, n¼6 patients.
(b, c) Immunohistochemical staining for cyclobutane pyrimidine dimers
(CPDs) in lesional psoriatic skin (b) before and (c) 15minutes after irradiation
with 70% MED. Dotted line indicates dermal/epidermal junction.
Scale bars¼ 200mm.
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axis was only observed in clinical responders (Johnson-
Huang et al., 2010). Collectively, these results indicate that
the in vivo downregulation of the Th1 and Th17 pathways is
achievable via intervention in different specific molecular
pathways (tumor necrosis factor, calcineurin, costimulatory
adhesion molecules, and UV receptors) and that it is crucial
for the clinical efficacy of antipsoriatic treatments.
In our study, expression of Th17 pathway genes was
suppressed in both lesional and nonlesional skin by NB-UVB
therapy. NB-UVB irradiation inhibited the Th17/IL-23-
dependent psoriasiform dermatitis in mice, and this
was accompanied by decreased STAT3 phosphorylation in
the epidermis. Inhibition of the Th17 pathway was further
confirmed in skin explants where NB-UVB inhibited the
IL-22-induced phosphorylation of STAT3 and the induction of
b-defensin-2, at 6 hours after irradiation. This demonstrates
that NB-UVB irradiation exerts a rapid inhibitory effect on the
Th17 pathway. The exact mechanism of STAT3 inhibition
by NB-UVB has yet to be determined. In primary human
keratinocytes, inhibition of STAT3 activation by UVB was
reversed by vanadate, a general inhibitor of tyrosine
phosphatases, indicating the involvement of at least a
tyrosine phosphatase in UVB-induced STAT3 inhibition (Sano
et al., 2005). Interestingly, STAT3 phosphorylation is also
inhibited by the reactive oxygen species-inducer manumycin
in cancer cells (Dixit et al., 2009). As reactive oxygen species
are also generated during NB-UVB irradiation, they might
also be involved in the inhibition of STAT3 phosphorylation
by NB-UVB. Nevertheless, the link between the immediate
biological effects of UVB via its cellular receptors (DNA,
reactive oxygen species, membrane changes, aryl-hydrocar-
bone receptor, and inflammasome) and its antipsoriatic/anti-
inflammatory effects has yet to be identified.
Type I IFNs are mainly produced by plasmacytoid DCs in
autoimmune diseases such as systemic lupus erythematodes
(Banchereau and Pascual, 2006), and during the innate
immune response to viral infections. Type I IFNs are critical
in the pathogenesis of psoriasis (Funk et al., 1991; Pauluzzi
et al., 1993; Downs and Dunnill, 2000; van der Fits et al.,
2004; Ketikoglou et al., 2005). Treatment of patients with
pre-existing psoriasis or with a familial predisposition for
psoriasis with IFN-a can induce or exacerbate the disease
(Funk et al., 1991; Pauluzzi et al., 1993; Downs and Dunnill,
2000; Ketikoglou et al., 2005). We have previously shown
that the type I IFN pathway is activated in lesional psoriatic
skin (van der Fits et al., 2004). The pathophysiological
relevance of type I IFN was demonstrated in a xenograft
murine model of psoriasis, where blocking of IFN-a
prevented the development of psoriatic lesions in trans-
planted nonlesional skin (Nestle et al., 2005). IFN-g, a type II
IFN, is mainly produced by activated Th1 cells present in
psoriatic lesions and it has been shown to induce the
regenerative psoriatic phenotype in healthy skin (Wei et al.,
1999). NB-UVB is known to deplete hematopoietic cells
such as T lymphocytes and Langerhans cells from the skin
(Ozawa et al., 1999; DeSilva et al., 2008). It is conceivable
that the observed inhibition of both type I and type II IFN
signaling pathways are because of depletion or inhibition of
lymphocytes and plasmacytoid DCs from psoriatic lesions
by NB-UVB.
Psoriatic lesions show several signs of altered epidermal
differentiation clinically and histologically (Tschachler,
2007). The importance of keratinocyte differentiation in the
pathogenesis of psoriasis is highlighted by the fact that
genetic alterations in the epidermal differentiation complex
on chromosome 1q21 (de Cid et al., 2009; Zhang et al.,
2009) and around the corneodesmosin gene on chromosome
6p21 (Orru et al., 2005) are closely associated with psoriasis.
NB-UVB phototherapy drives the expression of epidermal
differentiation-associated genes in the psoriatic lesions
toward the expression observed in normal, healthy skin.
A surprising finding in our study was that at 6 hours after
the first UV irradiation, many more genes were differentially
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Figure 6. Comparison of epidermal gene modulation in nonlesional skin of
narrow-band ultraviolet-B (NB-UVB)- and ustekinumab-treated patients
with psoriasis. Nonlesional epidermal samples were collected from patients
with psoriasis before treatment and at 50% psoriasis area and severity index
(PASI) reduction after treatment with NB-UVB or with ustekinumab, a
monoclonal anti-IL12/23p40 antibody. The expression of (a) S100 calcium
binding protein A7 (S100A7), (b) b-defensin-2, (c) IFN induced with helicase
C domain 1 (IFIH1), and (d) GATA3 mRNA was quantified using real-time
PCR (RT-PCR), with Abelson murine leukemia viral (v-abl) oncogene homolog
1 (ABL1) as an internal control gene (in ustekinumab-treated patients, n¼8)
or with microarray (NB-UVB-treated patients, n¼2, pools of 4 patients each).
Expression values at 50% PASI reduction are shown as percentages of the
expression values before treatment in both sets of data.
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expressed in nonlesional skin than in lesional skin, with only
three genes differentially expressed in lesional skin. This has
not been reported before as previous studies on the genomic
effects of NB-UVB in the skin used normal skin or cultured
keratinocytes (Li et al., 2001; Sesto et al., 2002; Takao et al.,
2002; Enk et al., 2006), or only nonlesional skin from patients
with psoriasis (Hochberg et al., 2007). We excluded the
possibility of incomplete UV penetration in lesional skin by
demonstrating that CPDs occur throughout the lesional
epidermis and in the superficial dermis, already 15minutes
after a single UV irradiation.
The resistance of psoriatic skin to UVB may be because of
powerful inflammatory stimuli from the infiltrating immune
cells that induce and sustain high transcription levels for
many genes. The modulation of more genes in lesional skin at
6 hours after NB-UVB irradiation, when 50% clinical
improvement (PASI) was reached, supports this concept.
Our results also imply that the effects of UVB in noninflamed
skin cannot simply be extrapolated to inflamed skin.
In conclusion, clinically effective NB-UVB therapy is
associated with downregulation of the critical Th17, type I,
and type II IFN signaling pathways and genes involved
in keratinocyte differentiation in lesional psoriatic skin.
In addition, several anti-inflammatory pathways, such as
glucocorticoid, vitamin D, peroxisome proliferator-activated
receptor, and IL-4 signaling, are modulated by NB-UVB
therapy. Our data underscore the importance of these
pathways in the pathogenesis of psoriasis and identify
them as targets of NB-UVB in the resolution of psoriatic
inflammation.
PATIENTS AND METHODS
Patients and treatments
A total of 11 patients with psoriasis were recruited. All participants
gave written informed consent. The Medical Ethical Committee of
the Erasmus MC, University Medical Center, Rotterdam, The
Netherlands, approved this study under the registration no.
234.237/2003/210. Patients (10 men and 1 woman, aged 20–73
years) had PASI scores of at least 10 (Supplementary Table S4 online)
and did not receive systemic therapy for at least 1 month or topical
therapy for at least 2 weeks before the start of the study. For
treatment specifications, see Supplementary Material online.
In a parallel unrelated study, 8 patients with psoriasis (6 women, 5
men, mean age 49 years, range 29–71 years) were recruited. All of
them gave written informed consent. The Medical Ethical Committee
of the Erasmus MC, University Medical Center, Rotterdam, The
Netherlands, approved this study under the registration number
104.050/SPO/1990/30. Patients were treated with ustekinumab
(Stelara, Janssen-Cilag BV, Tilburg, The Netherlands), a monoclonal
anti-IL12/IL23 p40-antibody. Ustekinumab (45mg) was injected
subcutaneously at start, and at weeks 4 and 16.
The study was conducted according to the Declaration of
Helsinki Principles.
Mice and treatments
Induction of skin inflammation by daily imiquimod application in
BALB/c mice was performed as described previously (van der Fits
et al., 2009). Briefly, mice were treated daily with imiquimod on the
shaved back skin for 5 days. Every other day, starting on the first day
of the experiment, mice were irradiated with a Waldmann
irradiation device equipped with TL-01 UV 236-01 lamps (Wald-
mann Medizintechnik, Villingen-Schwenningen, Germany), or were
sham irradiated. The applied UVB dose was 70% of the minimal
erythema dose on the first day and it was increased each time by
10%. Scoring of the severity of skin inflammation was performed as
described previously (van der Fits et al., 2009). On the sixth day,
mice were killed and 3mm biopsy samples were taken from the back
skin. Details on the determination of the minimal erythema dose in
mice are provided in the Supplementary Material online. All animal
work was approved by the animal ethical committee of the Erasmus
University Medical Center Rotterdam, The Netherlands, under
approval number DEC EUR 851 (OZP 128-06-07).
Biopsy samples, RNA extraction, and microarray analysis
Biopsies (3mm) were taken from psoriasis lesional and nonlesional
skin before the start of NB-UVB therapy and after the last treatment
session. To investigate the short-term effects of UVB, biopsies were
taken 6 hours after the first irradiation. When PASI scores were
reduced to 50% of the baseline score, additional biopsies from
lesional and nonlesional skin were taken before and 6hours after
UVB irradiation. For CPD immunohistochemistry, lesional and
nonlesional skin biopsies were taken from three patients before
and 15minutes after the first treatment session of NB-UVB
phototherapy. From patients treated with ustekinumab, 3-mm biopsy
samples were taken from nonlesional skin before the start of the
treatment and at 50% PASI score reduction. For details on RNA
extraction, see Supplementary Material online, as well as for details
on array hybridization and analysis.
Pathway analysis
The lists of genes differentially expressed in psoriasis lesions before
and after NB-UVB therapy were subjected to Ingenuity Pathway
Analysis (Ingenuity Systems) to identify signaling pathways repre-
sented by these genes. In addition, functional annotation of these
genes was performed using the Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID; Dennis et al., 2003).
Immunohistochemistry
To validate the microarray results at the protein level, immunostain-
ings were performed on biopsies from psoriasis lesions as described
previously (van der Fits et al., 2004). For immunofluorescent
staining, cryosections were fixed for 10minutes in 4% paraformal-
dehyde in phosphate-buffered saline. Before staining with anti-CPD
antibody, DNA was denatured using 0.07M NaOH in 70% ethanol,
and slides were preincubated with 5% normal rabbit serum in
phosphate-buffered saline with 0.1% BSA. Primary antibodies and
the applied dilutions are shown in Supplementary Table S7 online.
Relevant FITC-, Cy5-, or TxR-conjugated antibodies (1:100; Abcam,
Cambridge, UK) were used to detect primary antibodies. All
fluorescent images were made with an Axio Imager (Carl Zeiss BV,
Sliedrecht, The Netherlands) fluorescence microscope.
Skin organ culture
Normal skin biopsies were obtained from healthy volunteers
undergoing breast surgery in the Department of Plastic Surgery of
the Sint Franciscus Gasthuis, Rotterdam, The Netherlands, after
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informed consent. Biopsies were cultured as described previously
(Companjen et al., 2001). Recombinant human IL-22 (50 ngml–1;
R&D Systems, Abingdon, UK) was added to the culture medium, and
16 hours later biopsies were irradiated with NB-UVB using a small
Waldmann irradiation device equipped with TL-01 UV 236-01
lamps (Waldmann Medizintechnik). In all experiments, a single
NB-UVB dose of 600mJ cm–2 was used, representing a dose that is
usually reached within 3–9 clinical UVB therapy sessions (1–3 weeks
of clinical treatment). Biopsies were collected 6 hours after UV
irradiation. One of the four biopsies was snap-frozen, whereas the
epidermis of the three other biopsies was separated from the dermis
and total messenger RNA was isolated as described above.
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